Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS One. 2014 Jan 20;9(1):e85509. doi: 10.1371/journal.pone.0085509. eCollection 2014.

MMP9 processing of HSPB1 regulates tumor progression.

Author information

  • 1Division of Radiation Effects, Korea Institute of Radiological & Medical Sciences, Seoul, Korea ; School of Life Sciences and Biotechnology, Korea University, Seoul, Korea.
  • 2Division of Radiation Effects, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
  • 3College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea.
  • 4Laboratory of Tissue Engineering, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
  • 5School of Life Sciences and Biotechnology, Korea University, Seoul, Korea.
  • 6Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.

Abstract

Matrix metalloproteinases regulate pathophysiological events by processing matrix proteins and secreted proteins. Previously, we demonstrated that soluble heat shock protein B1 (HSPB1) is released primarily from endothelial cells (ECs) and regulates angiogenesis via direct interaction with vascular endothelial growth factor (VEGF). Here we report that MMP9 can cleave HSPB1 and release anti-angiogenic fragments, which play a key role in tumorprogression. We mapped the cleavage sites and explored their physiological relevance during these processing events. HSPB1 cleavage by MMP9 inhibited VEGF-induced ECs activation and the C-terminal HSPB1 fragment exhibited more interaction with VEGF than did full-length HSPB1. HSPB1 cleavage occurs during B16F10 lung progression in wild-type mice. Also, intact HSPB1 was more detected on tumor endothelium of MMP9 null mice than wild type mice. Finally, we confirmed that secretion of C-terminal HSPB1 fragment was significantly inhibited lung and liver tumor progression of B16F10 melanoma cells and lung tumor progression of CT26 colon carcinoma cells, compared to full-length HSPB1. These data suggest that in vivo MMP9-mediated processing of HSPB1 acts to regulate VEGF-induced ECs activation for tumor progression, releasing anti-angiogenic HSPB1 fragments. Moreover, these findings potentially explain an anti-target effect for the failure of MMP inhibitors in clinical trials, suggesting that MMP inhibitors may have pro-tumorigenic effects by reducing HSPB1 fragmentation.

PMID:
24465581
[PubMed - indexed for MEDLINE]
PMCID:
PMC3896397
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk